MCRB
Price
$18.50
Change
-$1.02 (-5.23%)
Updated
Sep 3 closing price
Capitalization
161.96M
RGNX
Price
$9.86
Change
+$0.74 (+8.11%)
Updated
Sep 3 closing price
Capitalization
498.58M
62 days until earnings call
Interact to see
Advertisement

MCRB vs RGNX

Header iconMCRB vs RGNX Comparison
Open Charts MCRB vs RGNXBanner chart's image
Seres Therapeutics
Price$18.50
Change-$1.02 (-5.23%)
Volume$105.35K
Capitalization161.96M
REGENXBIO
Price$9.86
Change+$0.74 (+8.11%)
Volume$619.03K
Capitalization498.58M
MCRB vs RGNX Comparison Chart in %
Loading...
MCRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MCRB vs. RGNX commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MCRB is a Hold and RGNX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (MCRB: $18.50 vs. RGNX: $9.86)
Brand notoriety: MCRB and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MCRB: 75% vs. RGNX: 99%
Market capitalization -- MCRB: $161.96M vs. RGNX: $498.58M
MCRB [@Biotechnology] is valued at $161.96M. RGNX’s [@Biotechnology] market capitalization is $498.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MCRB’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • MCRB’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, MCRB is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MCRB’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 7 bullish TA indicator(s).

  • MCRB’s TA Score: 4 bullish, 5 bearish.
  • RGNX’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than MCRB.

Price Growth

MCRB (@Biotechnology) experienced а -2.01% price change this week, while RGNX (@Biotechnology) price change was +11.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.29%. For the same industry, the average monthly price growth was +15.06%, and the average quarterly price growth was +30.89%.

Reported Earning Dates

RGNX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+0.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($499M) has a higher market cap than MCRB($162M). RGNX (17.982) and MCRB (17.449) have similar YTD gains . MCRB has higher annual earnings (EBITDA): -49.22M vs. RGNX (-129.93M). RGNX has more cash in the bank: 323M vs. MCRB (45.4M). RGNX has less debt than MCRB: RGNX (77.7M) vs MCRB (87.4M). RGNX has higher revenues than MCRB: RGNX (156M) vs MCRB (0).
MCRBRGNXMCRB / RGNX
Capitalization162M499M32%
EBITDA-49.22M-129.93M38%
Gain YTD17.44917.98297%
P/E RatioN/AN/A-
Revenue0156M-
Total Cash45.4M323M14%
Total Debt87.4M77.7M112%
FUNDAMENTALS RATINGS
MCRB vs RGNX: Fundamental Ratings
MCRB
RGNX
OUTLOOK RATING
1..100
246
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3653
P/E GROWTH RATING
1..100
10022
SEASONALITY SCORE
1..100
7590

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MCRB's Valuation (44) in the Biotechnology industry is in the same range as RGNX (70). This means that MCRB’s stock grew similarly to RGNX’s over the last 12 months.

MCRB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that MCRB’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's SMR Rating (98) in the Biotechnology industry is in the same range as MCRB (100). This means that RGNX’s stock grew similarly to MCRB’s over the last 12 months.

MCRB's Price Growth Rating (36) in the Biotechnology industry is in the same range as RGNX (53). This means that MCRB’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for MCRB (100). This means that RGNX’s stock grew significantly faster than MCRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MCRBRGNX
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 13 days ago
82%
Bullish Trend 13 days ago
77%
Declines
ODDS (%)
Bearish Trend 29 days ago
89%
Bearish Trend 16 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
MCRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GHAIX46.60-0.04
-0.09%
VanEck Global Resources Fund I
JHDFX19.22-0.04
-0.21%
JPMorgan Hedged Equity 2 R5
THOCX42.94-0.30
-0.69%
Thornburg Global Opportunities C
DHIAX19.90-0.16
-0.80%
Diamond Hill International Inv
PETZX14.57-0.30
-2.02%
Gabelli Pet Parents'™

MCRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, MCRB has been loosely correlated with RIGL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if MCRB jumps, then RIGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MCRB
1D Price
Change %
MCRB100%
+3.06%
RIGL - MCRB
38%
Loosely correlated
-1.00%
MTVA - MCRB
33%
Poorly correlated
+0.44%
OTLK - MCRB
32%
Poorly correlated
+2.22%
ATXS - MCRB
29%
Poorly correlated
+6.63%
RGNX - MCRB
28%
Poorly correlated
+2.13%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+2.13%
SYRE - RGNX
54%
Loosely correlated
+0.85%
DNLI - RGNX
54%
Loosely correlated
+1.18%
VYGR - RGNX
53%
Loosely correlated
+6.55%
IDYA - RGNX
53%
Loosely correlated
+3.79%
MGNX - RGNX
52%
Loosely correlated
-1.69%
More